| 2026-08-17 | 8-K | Form 8-K, Item 8.01 |
| 2026-08-06 | Deck | Corporate Presentation |
| 2026-08-06 | Press release | Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-08-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-06 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-23 | Press release | Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026 |
| 2026-07-02 | 8-K | Form 8-K, Item 2.03 |
| 2026-06-17 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-19 | Press release | Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026 |
| 2026-05-07 | Press release | Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings |
| 2026-04-30 | Press release | Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-04-30 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-30 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-29 | Proxy | Definitive proxy statement |
| 2026-04-27 | Press release | Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings |
| 2026-04-23 | Press release | Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week |
| 2026-04-20 | Press release | Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer |
| 2026-04-16 | Press release | Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026 |
| 2026-04-01 | Press release | Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx |
| 2026-03-09 | Press release | Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IB |
| 2026-03-04 | Press release | Ardelyx to Participate in Upcoming Investor Conferences |
| 2026-02-24 | Press release | Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions |
| 2026-02-21 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-19 | Press release | Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update |
| 2026-02-19 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-19 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-05 | Press release | Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026 |
| 2026-01-28 | Press release | First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA |
| 2026-01-08 | Press release | Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook |
| 2026-01-08 | 8-K | Form 8-K, Item 2.02 results |
| 2025-12-17 | 8-K | Form 8-K, Item 5.02 |
| 2025-10-30 | Press release | Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update |
| 2025-10-30 | 8-K | Form 8-K, Item 2.02 results |
| 2025-10-30 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-14 | 8-K | Form 8-K, Item 5.02 |
| 2025-10-13 | Press release | Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025 |
| 2025-08-04 | Press release | Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update |
| 2025-08-04 | 8-K | Form 8-K, Item 2.02 results |
| 2025-08-04 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2025-07-21 | Press release | Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025 |